Answers are grounded in this paper and cite their sources.
This prospective study aimed to evaluate changes in disease-specific and general health-related quality of life, fatigue, depression, and anxiety among adults with Crohn's disease before and after at least six months of treatment with biological agents. A total of 97 adult individuals with CD were prospectively recruited between May 2024 and August 2025. These participants underwent treatment with biological agents, which included infliximab, adalimumab, ustekinumab, or vedolizumab. Standardized measures for HRQoL and psychological outcomes were gathered. To evaluate these outcomes, a variety of tools were utilized, including the Inflammatory Bowel Disease Questionnaire (IBDQ), Crohn's Symptom Severity (CSS), the 36-item Short Form Survey (SF-36), EuroQol 5-Dimension 5-Level (EQ-5D-5L), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9). These assessments were conducted both before treatment and after at least six months of therapy. Statistical analyses employed paired sample t-tests and non-parametric methods, with statistical significance determined at P < 0.05. The cohort had a mean age of 26.34 years, predominantly male (81.44%), and mainly presented with mild disease (67.01%). Significant improvements were observed in disease-specific HRQoL, with the IBDQ total score increasing from 95.36 ± 13.81 pre-treatment to 122.80 ± 17.80 post-treatment (P < 0.001). Disease severity, as measured by the CSS, decreased significantly from 47.38 ± 5.84 to 38.21 ± 6.67 (P < 0.001). General HRQoL also showed substantial improvement, with SF-36 PCS and MCS scores increasing by 5.00 points (P < 0.001 for both), and the EQ-5D-5L VAS score improving by 11.33 points (P < 0.001). Fatigue, measured by FACIT-F, improved significantly by 9.18 points (P < 0.001). Psychological outcomes also showed notable improvement, with the PHQ-9 score decreasing from 14.28 ± 3.66 to 6.32 ± 4.39 (P < 0.001) and the GAD-7 score decreasing from 12.20 ± 3.15 to 7.22 ± 3.54 (P < 0.001). Biological therapy in individuals with CD was associated with improvements in disease-specific and general HRQoL and reductions in symptom severity, fatigue, depression, and anxiety. These findings support the value of incorporating patient-reported quality-of-life and psychological assessments into biologic-treatment follow-up and comprehensive CD care.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: